Hospira, Inc. (HSP)
$46.59
-0.57 (-1.21%)
| CAPS Rating |
|
|---|---|
| Open | $47.17 |
| Previous Close | $47.16 |
| Daily Range | $46.48 - $47.23 |
| 52-Week Range | $21.21 - $48.23 |
| Market Cap | $7.56B |
| P/E Ratio | 18.28 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 882,489 |
| Average Daily Volume | 1,017,000 |
HSP
VS S&P 500 (SPY)
How do you think HSP will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
HSP Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
HSP News and Commentary
- HSP .90 eps qtr shows that its newly launched Chemo drug will have a major effect – Blog at The Motley Fool
- Watch RDY based on Generic Drug HSP results today. – Blog at The Motley Fool
- UPDATE 1-Hospira Q3 net profit up, boosts outlook – Reuters
- UPDATE 1-US FDA probing Abbott, Hospira device cords – Reuters
- 4-Star Stocks on the Upswing – The Motley Fool
- UPDATE 1-Hospira in deal with Celltrion on biogenerics – Reuters
- UPDATE 1-Hospira gains global biogeneric rights from Teva – Reuters
- Genzyme's Good News. Finally! – The Motley Fool
- 5-Star Stocks on the Upswing – The Motley Fool
- UPDATE 1-Hospira boosts full-year profit forecast – Reuters
- This Might Be Your Perfect Investment – The Motley Fool
- HSP got FDA approval for Generic , another hit to Pfizer as Generic makers keep taking share. – Blog at The Motley Fool
- Are These Winners Worth the Risk? – The Motley Fool
- Novartis Leads the Pack – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- The Easy Way to Develop Drugs – The Motley Fool
- Don't Miss These Stocks – The Motley Fool
- Today's 5-Star Movers – The Motley Fool
- The Truth Behind Buffett's Big Bet – The Motley Fool
- The Truth Behind Buffett's Big Bet – The Motley Fool
RSS Headlines
Fool UK
